Streetbeat News

Regulatory

COUR

CREV

WINT

Market-Moving News for July 26th: Carbon Revolution (CREV) teams up with GM to provide carbon fiber wheels for the Chevrolet Corvette ZR1, Windtree Therapeutics (WINT) withdraws its registration statement, and Coursera (COUR) shares rise after beating Q2 earnings estimates.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 12:22 pm

CLLS

Cellectis shares are trading higher after the company announced the FDA granted orphan drug and rare pediatric designation disease to UCART22.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 12:20 pm

BABA

META

NVDA

Alibaba and Tencent have integrated Meta's latest AI model, Llama 3.1, into their cloud services. This move comes amid strained U.S.-China relations and advanced semiconductor sanctions. Alibaba's stock has been under pressure, losing over 22% in the last 12 months.

Portfolio Pulse from Anusuya Lahiri

July 26, 2024 | 12:15 pm

PFC

Trading for PFC was halted at 8:05:00 a.m. ET due to pending news. Investors should stay tuned for further updates.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 12:05 pm

MEDS

Trading for the stock MEDS has been halted as of 7:55:00 a.m. ET pending news. Investors should stay tuned for further updates.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 11:55 am

BIIB

Biogen shares are trading lower after the European Medicines Agency adopted a negative opinion on the Marketing Authorization Approval for lecanemab.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 11:44 am

GERN

Geron Corporation announced that the updated NCCN guidelines now recommend RYTELO (Imetelstat) for the treatment of symptomatic anemia in patients with lower-risk MDS.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 11:36 am

BIIB

ESALF

The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a negative opinion on the approval of Eisai and Biogen's Lecanemab for early Alzheimer's treatment. Eisai plans to seek re-examination and work with authorities to make the treatment available in the EU.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 11:24 am

CMMB

Chemomab Therapeutics has regained compliance with Nasdaq's minimum bid price requirement after its ADSs maintained a closing bid price of $1.00 or greater for 10 consecutive business days.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 11:08 am

MRK

The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of Merck's Keytruda in combination with Padcev (Enfortumab Vedotin) for the first-line treatment of unresectable or metastatic conditions.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 10:54 am